Abstract | OBJECTIVE: DESIGN: A multicenter, prospective, nonrandomized trial. SETTING: University medical centers and community hospitals. PATIENTS: Sixty-seven patients were registered, 28 were excluded, and 39 patients were evaluable for response (median age, 59 years; range, 25 to 82 years) (stages I and II, 10%; stages III and IV, 90%; B symptoms, 74%). MEASUREMENTS: Response, survival, and relapse. INTERVENTION: Patients initially received prednisone and no further treatment if a complete remission was achieved. Relapsing or refractory patients were treated with COPBLAM/IMVP-16. Patients with life-threatening tumor progression or extension received COPBLAM/IMVP-16 initially. Treatments were chosen in accordance with tumor extension and response to prednisone. Treatment modalities were not compared. RESULTS: Twenty-eight patients received primary prednisone, 18 received secondary prednisone, and 11 received primary chemotherapy. The complete response rates (with 95% CIs) were 29% (CI, 12% to 46%), 56% (CI, 33% to 79%), and 64% (CI, 36% to 92%), respectively. The median observation time of surviving patients was 28 months (range, 7 to 53). The median overall survival time was 15 months. The probabilities (with 95% CIs) of overall survival, event-free survival, and relapse at 36 months were 40.5% (CI, 24% to 56%), 32.3% (CI, 17% to 47%), and 34.6% (CI, 14% to 56%), respectively. At the time of evaluation, 22 of 39 patients had died, 7 of noninfectious complications and 14 of infections. CONCLUSIONS:
Prednisone with or without COPBLAM/IMVP-16 treatment in AILD-type lymphoma leads to complete remissions in about half of the patients and in long-term, disease-free survival for one third.
|
Authors | W Siegert, A Agthe, H Griesser, R Schwerdtfeger, G Brittinger, M Engelhard, R Kuse, M Tiemann, K Lennert, D Huhn |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 117
Issue 5
Pg. 364-70
(Sep 01 1992)
ISSN: 0003-4819 [Print] United States |
PMID | 1380221
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Bleomycin
- Procarbazine
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Ifosfamide
- Prednisone
- Methotrexate
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bleomycin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Doxorubicin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Humans
- Ifosfamide
(administration & dosage)
- Immunoblastic Lymphadenopathy
(drug therapy)
- Lymphoma, T-Cell
(drug therapy)
- Male
- Methotrexate
(administration & dosage)
- Middle Aged
- Prednisone
(administration & dosage, therapeutic use)
- Procarbazine
(administration & dosage)
- Prospective Studies
- Survival Analysis
- Vincristine
(administration & dosage)
|